Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Goldman Sachs Maintains Neutral on TG Therapeutics, Raises Price Target to $20

Author: Benzinga Newsdesk | August 07, 2024 12:19pm
Goldman Sachs analyst Corinne Jenkins maintains TG Therapeutics (NASDAQ:TGTX) with a Neutral and raises the price target from $18 to $20.

Posted In: TGTX

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist